ASCO26: key readouts in lung cancer
Pumitamig demonstrates a 70 % overall response rate in untreated non‑small cell lung cancer, comparable to other PD‑(L)1/VEGF agents.
This article summarizes pivotal readouts from the 2026 American Society of Clinical Oncology (ASCO) Congress focusing on non‑small cell lung cancer (NSCLC). Key highlights include interim Phase II data for the PD‑(L)1/VEGF bispecific pumitamig achieving 70 % ORR, the RET‑specific RET inhibitor lunbotinib fumarate showing 81 %–87 % ORR in RET‑positive NSCLC, the combination of amivantamab (Rybrevant) and lazertinib (Lazcluze) for atypical EGFR mutations, and long‑term progression‑free survival results from Lorbrena (lorlatinib) in ALK‑positive advanced NSCLC.
These data suggest several novel targeted approaches may soon change first‑line therapy in NSCLC subtypes, offering higher response rates, durable disease control, and improved central nervous system benefit, thereby potentially improving survival and quality of life for patients with historically limited options.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT